{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:43:25Z","timestamp":1793295805285,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-30367-w","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:51:32Z","timestamp":1764946292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase I study of pevonedistat combined with capecitabine and oxaliplatin in patients with platinum-refractory advanced gastric cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Hirokazu","family":"Shoji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ooki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"30367_CR1","unstructured":"The GLOBOCAN 2022 database on the Global Cancer Observatory website. https:\/\/gco.iarc.fr\/. (Accessed 24 November 2024)."},{"key":"30367_CR2","unstructured":"Vital Statistics Japan (Ministry of Health, Labour and Welfare)."},{"issue":"1","key":"30367_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada, Y. et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer. Ann. Oncol. 26(1), 141\u2013148 (2015).","journal-title":"Ann. Oncol."},{"issue":"17","key":"30367_CR4","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.23.01601","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. J. Clin. Oncol. 42(17), 2012\u20132020 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"30367_CR5","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s10120-024-01535-0","volume":"27","author":"N Boku","year":"2024","unstructured":"Boku, N. et al. Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial. Gastric Cancer 27(6), 1287\u20131301 (2024).","journal-title":"Gastric Cancer"},{"issue":"11","key":"30367_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24(11), 1181\u20131195 (2023).","journal-title":"Lancet Oncol."},{"issue":"35","key":"30367_CR7","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","volume":"31","author":"S Hironaka","year":"2013","unstructured":"Hironaka, S. et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J. Clin. Oncol. 31(35), 4438\u20134444 (2013).","journal-title":"J. Clin. Oncol."},{"issue":"10111","key":"30367_CR8","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang, Y. K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10111), 2461\u20132471 (2017).","journal-title":"Lancet"},{"issue":"11","key":"30367_CR9","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara, K. et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 19(11), 1437\u20131448 (2018).","journal-title":"Lancet Oncol."},{"issue":"25","key":"30367_CR10","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara, K. et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med. 382(25), 2419\u20132430 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"30367_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrc1881","volume":"6","author":"KI Nakayama","year":"2006","unstructured":"Nakayama, K. I. & Nakayama, K. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 6(5), 369\u2013381 (2006).","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"30367_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2174\/156800911794519734","volume":"11","author":"L Jia","year":"2011","unstructured":"Jia, L. & Sun, Y. SCF E3 ubiquitin ligases as anticancer targets. Curr. Cancer Drug Targets 11(3), 347\u2013356 (2011).","journal-title":"Curr. Cancer Drug Targets"},{"issue":"8","key":"30367_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1593\/neo.06376","volume":"8","author":"Y Sun","year":"2006","unstructured":"Sun, Y. E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 8(8), 645\u2013654 (2006).","journal-title":"Neoplasia"},{"issue":"2","key":"30367_CR14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1172\/JCI70297","volume":"124","author":"H Li","year":"2014","unstructured":"Li, H. et al. Inactivation of SAG\/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis. J. Clin. Invest. 124(2), 835\u2013846 (2014).","journal-title":"J. Clin. Invest."},{"issue":"2","key":"30367_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s13238-012-2105-7","volume":"4","author":"Y Sun","year":"2013","unstructured":"Sun, Y. & Li, H. Functional characterization of SAG\/RBX2\/ROC2\/RNF7, an antioxidant protein and an E3 ubiquitin ligase. Protein Cell 4(2), 103\u2013116 (2013).","journal-title":"Protein Cell"},{"issue":"4","key":"30367_CR16","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0002-9440(10)63393-7","volume":"165","author":"P Karakaidos","year":"2004","unstructured":"Karakaidos, P. et al. Overexpression of the replication licensing regulators hCdt1 and hCdc6 characterizes a subset of non-small-cell lung carcinomas: synergistic effect with mutant p53 on tumor growth and chromosomal instability\u2013evidence of E2F\u20131 transcriptional control over hCdt1. Am. J. Pathol. 165(4), 1351\u20131365 (2004).","journal-title":"Am. J. Pathol."},{"issue":"7239","key":"30367_CR17","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","volume":"458","author":"TA Soucy","year":"2009","unstructured":"Soucy, T. A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458(7239), 732\u2013736 (2009).","journal-title":"Nature"},{"issue":"4","key":"30367_CR18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjh.13323","volume":"169","author":"RT Swords","year":"2015","unstructured":"Swords, R. T. et al. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br. J. Haematol. 169(4), 534\u2013543 (2015).","journal-title":"Br. J. Haematol."},{"issue":"9","key":"30367_CR19","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","volume":"116","author":"MA Milhollen","year":"2010","unstructured":"Milhollen, M. A. et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 116(9), 1515\u20131523 (2010).","journal-title":"Blood"},{"issue":"1","key":"30367_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/1078-0432.CCR-15-1237","volume":"22","author":"JJ Shah","year":"2016","unstructured":"Shah, J. J. et al. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in patients with relapsed\/refractory multiple myeloma or lymphoma. Clin. Cancer Res. 22(1), 34\u201343 (2016).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"30367_CR21","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.1038\/bcj.2017.1","volume":"7","author":"RT Swords","year":"2017","unstructured":"Swords, R. T. et al. Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood Cancer J. 7(2), e520 (2017).","journal-title":"Blood Cancer J."},{"issue":"13","key":"30367_CR22","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1182\/blood-2017-09-805895","volume":"131","author":"RT Swords","year":"2018","unstructured":"Swords, R. T. et al. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood 131(13), 1415\u20131424 (2018).","journal-title":"Blood"},{"key":"30367_CR23","doi-asserted-by":"publisher","first-page":"24218","DOI":"10.1038\/srep24218","volume":"6","author":"H Lan","year":"2016","unstructured":"Lan, H. et al. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells. Sci. Rep. 6, 24218 (2016).","journal-title":"Sci. Rep."},{"issue":"7","key":"30367_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrm3822","volume":"15","author":"JA Marteijn","year":"2014","unstructured":"Marteijn, J. A. et al. Understanding nucleotide excision repair and its roles in cancer and ageing. Nat. Rev. Mol. Cell. Biol. 15(7), 465\u2013481 (2014).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"5","key":"30367_CR25","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s10120-018-0815-0","volume":"21","author":"K Nishikawa","year":"2018","unstructured":"Nishikawa, K. et al. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial. Gastric Cancer 21(5), 811\u2013818 (2018).","journal-title":"Gastric Cancer"},{"issue":"4","key":"30367_CR26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ejca.2011.12.017","volume":"48","author":"GM Kim","year":"2012","unstructured":"Kim, G. M. et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur. J. Cancer 48(4), 518\u2013526 (2012).","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"30367_CR27","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s10147-019-01425-x","volume":"24","author":"G Wang","year":"2019","unstructured":"Wang, G. et al. Efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of gastric cancer: a meta-analysis of randomized controlled trials. Int. J. Clin. Oncol. 24(6), 614\u2013623 (2019).","journal-title":"Int. J. Clin. Oncol."},{"issue":"2","key":"30367_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"30367_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10637-016-0348-5","volume":"34","author":"S Bhatia","year":"2016","unstructured":"Bhatia, S. et al. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924\/MLN4924) in patients with metastatic melanoma. Invest. New Drugs 34(4), 439\u2013449 (2016).","journal-title":"Invest. New Drugs"},{"issue":"1","key":"30367_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10637-018-0610-0","volume":"37","author":"AC Lockhart","year":"2019","unstructured":"Lockhart, A. C. et al. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. Invest. New Drugs 37(1), 87\u201397 (2019).","journal-title":"Invest. New Drugs"},{"issue":"1","key":"30367_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-022-01264-w","volume":"15","author":"H Handa","year":"2022","unstructured":"Handa, H. et al. Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1\/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine. J. Hematol. Oncol. 15(1), 56 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"30367_CR32","doi-asserted-by":"publisher","first-page":"114241","DOI":"10.1016\/j.ejca.2024.114241","volume":"209","author":"JH Foster","year":"2024","unstructured":"Foster, J. H. et al. Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615). Eur. J. Cancer 209, 114241 (2024).","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"30367_CR33","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1007\/s10637-022-01286-8","volume":"40","author":"X Zhou","year":"2022","unstructured":"Zhou, X. et al. Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. Invest. New Drugs 40(5), 1042\u20131050 (2022).","journal-title":"Invest. New Drugs"},{"issue":"2","key":"30367_CR34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.cllc.2023.10.011","volume":"25","author":"A Qin","year":"2024","unstructured":"Qin, A. et al. A phase II trial of pevonedistat and docetaxel in patients with previously treated advanced non-small-cell lung cancer. Clin. Lung Cancer 25(2), 128\u2013134 (2024).","journal-title":"Clin. Lung Cancer"},{"issue":"4","key":"30367_CR35","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1007\/s10637-020-01055-5","volume":"39","author":"N Yamamoto","year":"2021","unstructured":"Yamamoto, N. et al. A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors. Invest. New Drugs 39(4), 1036\u20131046 (2021).","journal-title":"Invest. New Drugs"},{"issue":"3","key":"30367_CR36","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/annonc\/mdh095","volume":"15","author":"L Rubbia-Brandt","year":"2004","unstructured":"Rubbia-Brandt, L. et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann. Oncol. 15(3), 460\u2013466 (2004).","journal-title":"Ann. Oncol."},{"issue":"13","key":"30367_CR37","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1200\/JCO.2005.05.3074","volume":"24","author":"JN Vauthey","year":"2006","unstructured":"Vauthey, J. N. et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J. Clin. Oncol. 24(13), 2065\u20132072 (2006).","journal-title":"J. Clin. Oncol."},{"issue":"31","key":"30367_CR38","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1200\/JCO.2006.05.8156","volume":"24","author":"T Aloia","year":"2006","unstructured":"Aloia, T. et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J. Clin. Oncol. 24(31), 4983\u20134990 (2006).","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"30367_CR39","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1245\/s10434-012-2438-8","volume":"19","author":"SM Robinson","year":"2012","unstructured":"Robinson, S. M. et al. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann. Surg. Oncol. 19(13), 4287\u20134299 (2012).","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"30367_CR40","first-page":"378","volume":"16","author":"M Hussein","year":"2023","unstructured":"Hussein, M. & Jensen, A. B. Drug-induced liver injury caused by capecitabine: a case report and a literature review. Case Rep. Oncol. 16(1), 378\u2013384 (2023).","journal-title":"Case Rep. Oncol."},{"key":"30367_CR41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1746-1596-8-150","volume":"8","author":"S Gurzu","year":"2013","unstructured":"Gurzu, S. et al. Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman. Diagn. Pathol. 8, 150 (2013).","journal-title":"Diagn. Pathol."},{"key":"30367_CR42","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/1752-1947-4-227","volume":"4","author":"SN Chin","year":"2010","unstructured":"Chin, S. N., Kim, T. K. & Siu, L. L. Hepatic steatosis secondary to capecitabine: a case report. J. Med. Case Rep. 4, 227 (2010).","journal-title":"J. Med. Case Rep."},{"issue":"4","key":"30367_CR43","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s10120-016-0670-9","volume":"20","author":"T Nishimura","year":"2017","unstructured":"Nishimura, T. et al. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. Gastric Cancer 20(4), 655\u2013662 (2017).","journal-title":"Gastric Cancer"},{"issue":"4","key":"30367_CR44","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1007\/s10120-021-01173-w","volume":"24","author":"N Boku","year":"2021","unstructured":"Boku, N. et al. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer 24(4), 946\u2013958 (2021).","journal-title":"Gastric Cancer"},{"issue":"8","key":"30367_CR45","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/jjco\/hys084","volume":"42","author":"K Tsuji","year":"2012","unstructured":"Tsuji, K. et al. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study. Jpn. J. Clin. Oncol. 42(8), 686\u2013690 (2012).","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"6","key":"30367_CR46","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1007\/s10120-018-0825-y","volume":"21","author":"C Kondoh","year":"2018","unstructured":"Kondoh, C. et al. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan. Gastric Cancer 21(6), 1050\u20131057 (2018).","journal-title":"Gastric Cancer"},{"issue":"1","key":"30367_CR47","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4143\/crt.2010.42.1.24","volume":"42","author":"YS Kim","year":"2010","unstructured":"Kim, Y. S. et al. Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer. Cancer Res. Treat. 42(1), 24\u201329 (2010).","journal-title":"Cancer Res. Treat."},{"issue":"3","key":"30367_CR48","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/annonc\/mdg106","volume":"14","author":"DY Kim","year":"2003","unstructured":"Kim, D. Y. et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann. Oncol. 14(3), 383\u2013387 (2003).","journal-title":"Ann. Oncol."},{"issue":"5","key":"30367_CR49","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4143\/crt.2005.37.5.279","volume":"37","author":"SH Suh","year":"2005","unstructured":"Suh, S. H. et al. Oxaliplatin with biweekly low dose leucovorin and bolus and continuous infusion of 5-fluorouracil (modified FOLFOX 4) as a salvage therapy for patients with advanced gastric cancer. Cancer Res. Treat. 37(5), 279\u2013283 (2005).","journal-title":"Cancer Res. Treat."},{"issue":"3","key":"30367_CR50","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00280-008-0753-3","volume":"63","author":"HY Seo","year":"2009","unstructured":"Seo, H. Y. et al. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis. Cancer Chemother. Pharmacol. 63(3), 433\u2013439 (2009).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"10","key":"30367_CR51","doi-asserted-by":"publisher","first-page":"114774","DOI":"10.1016\/j.celrep.2024.114774","volume":"43","author":"H Shoji","year":"2024","unstructured":"Shoji, H. et al. Phosphoproteomic subtyping of gastric cancer reveals dynamic transformation with chemotherapy and guides targeted cancer treatment. Cell. Rep. 43(10), 114774 (2024).","journal-title":"Cell. Rep."},{"issue":"4","key":"30367_CR52","doi-asserted-by":"publisher","first-page":"104012","DOI":"10.1016\/j.isci.2022.104012","volume":"25","author":"S Muraoka","year":"2022","unstructured":"Muraoka, S. et al. Comprehensive proteomic profiling of plasma and serum phosphatidylserine-positive extracellular vesicles reveals tissue-specific proteins. iScience 25(4), 104012 (2022).","journal-title":"iScience"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30367-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30367-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30367-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:03:01Z","timestamp":1767830581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30367-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["30367"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-30367-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"25 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hirokazu Shoji reports honoraria from Ono Pharmaceutical and Bristol Myers Squibb, and research grants from Ono Pharmaceutical and Takeda Pharmaceuticals. Daisuke Takahari reports grants from Taiho Pharmaceutical, Ono Pharmaceutical, Eli Lilly, Chugai Pharmaceutical, Bristol-Myers Squibb, and Daiichi Sankyo. Akira Ooki reports honoraria from Bristol-Myers Squibb, Astellas Pharma, Merck Serono, Taiho Pharmaceutical, Daiichi Sankyo, Ono Pharmaceutical, and MSD. Hidekazu Hirano reports honoraria from Bristol-Myers Squibb, Chugai Pharmaceutical, Novartis, Taiho Pharmaceutical, Fujifilm Pharmaceuticals, Teijin Pharma, and Ono Pharmaceutical. Kengo Nagashima reports consulting fees from SENJU Pharmaceutical Co., Ltd., Toray Industries, Inc., Kowa Company, Ltd., and Eli Lilly. Kensei Yamaguchi reports honoraria from Bristol Myers Squibb KK, Eli Lilly Japan KK, Taiho Pharmaceutical Co., Ltd., and Ono. Ken Kato reports consulting fees from Ono Pharmaceutical, Bristol-Myers Squibb, BeiGene, Novartis Pharma, AstraZeneca, Roche, Bayer Yakuhin, Merck & Co, Merck Biopharma, and Janssen Pharmaceutical, reports honoraria from Bristol-Myers Squibb, and Ono Pharmaceutical and reports participation on a Data Safety Monitoring Board or Advisory Board of Ono Pharmaceutical, Chugai Pharmaceutical, Bristol-Myers Squibb, and Merck & Co. Narikazu Boku reports honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Taiho Pharmaceutical, Daiichi Sankyo, and Eli Lilly, reports participation on a Data Safety Monitoring Board or Advisory Board of Kyowa Kirin, and research grants from Takeda Pharmaceuticals. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"692"}}